Studies of the pathogenesis and management of thrombotic thrombocytopenic purpura. 1996

E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
2nd Department of Internal Medicine, Hyogo Medical College, Japan.

We have studied the pathophysiological signs and methods of management of thrombotic thrombocytopenic purpura (TTP) in our TTP patients. We showed that anti-platelet GP II b- III a monoclonal antibodies bound to human vascular endothelial cells (HUVEC). The binding rate of 125I-anti-platelet GP II b- III a monoclonal antibodies to HUVEC treated with TTP patients sera was decreased, compared with the value observed for HUVEC treated with normal sera. These findings showed that GP II b- III a like substances are expressed on HUVEC and that TTP patients sera appear to contain anti-platelet GP II b- III a antibodies which may attack and injure the endothelial cells. PGI2 stabilizing activity of plasma is measured by PGI2 inhibitory activity attenuation on normal platelet aggregation induced by ADP. PGI2 stabilizing activity decreases in acute phase, increases in remission, suggesting that there may be a relationship between pathogenesis of TTP and decreases of PGI2 stabilizing activity. We also showed that PGI2 analogue (beraprost sodium) was useful for prevention of relapse of TTP. Plasmapheresis has emerged as the treatment of choice of TTP. We found the effectiveness of the high molecular weight fraction (HMW-F) of plasma in chronic TTP patients. HMW-F of plasma may contain the main factor necessary for improvement of TTP.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011697 Purpura, Thrombotic Thrombocytopenic An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases. Moschkowitz Disease,Purpura, Thrombotic Thrombopenic,Thrombotic Thrombocytopenic Purpura, Congenital,Thrombotic Thrombocytopenic Purpura, Familial,Congenital Thrombotic Thrombocytopenic Purpura,Familial Thrombotic Thrombocytopenia Purpura,Familial Thrombotic Thrombocytopenic Purpura,Microangiopathic Hemolytic Anemia, Congenital,Moschcowitz Disease,Schulman-Upshaw Syndrome,Thrombotic Microangiopathy, Familial,Thrombotic Thrombocytopenic Purpura,Upshaw Factor, Deficiency of,Upshaw-Schulman Syndrome,Familial Thrombotic Microangiopathy,Microangiopathy, Familial Thrombotic,Schulman Upshaw Syndrome,Thrombocytopenic Purpura, Thrombotic,Thrombopenic Purpura, Thrombotic,Thrombotic Thrombopenic Purpura,Upshaw Schulman Syndrome
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
March 2003, Current hematology reports,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
April 1987, Seminars in hematology,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
January 1979, Seminars in thrombosis and hemostasis,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
June 2000, British journal of haematology,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
September 2017, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
June 2003, Current opinion in neurology,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
January 2010, International journal of hematology,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
January 2021, [Rinsho ketsueki] The Japanese journal of clinical hematology,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
January 1993, Nihon rinsho. Japanese journal of clinical medicine,
E Kakishita, and T Nakajima, and A Suehiro, and T Koyama, and M Ueda, and H Tsujioka, and H Yoshimoto
April 1989, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!